戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  testing whether UNC6852 could be used as an antithrombotic drug.
2 ate, and annual prevalence of treatment with antithrombotic drugs.
3 s and to test the efficacy and safety of new antithrombotic drugs.
4 n their antithrombotic effects than previous antithrombotic drugs.
5 intraocular bleeding between NOACs and other antithrombotic drugs.
6 CH, provoking uncertainties about the use of antithrombotic drugs.
7 recurrent ischaemic stroke when treated with antithrombotic drugs.
8 r (VWF) is a promising target for developing antithrombotic drugs.
9 ly more vulnerable to the adverse effects of antithrombotic drugs.
10 cial for developing safer and more effective antithrombotic drugs.
11 ts, platelet inhibitors, and combinations of antithrombotic drugs.
12 e potential targets for development of novel antithrombotic drugs.
13 ate of ICH, and prevalence of treatment with antithrombotic drugs.
14  Participants with a history of VTE who used antithrombotic drugs (1 year before index dates) or test
15 1.07 to 2.04; p = 0.02), and use of multiple antithrombotic drugs (adjusted HR: 1.33; 95% CI: 1.14 to
16 ife AF patients with indication for multiple antithrombotic drugs after MI/PCI, OAC and clopidogrel w
17 ased therapies (EBTs), 4% were not using any antithrombotic drug and only 1.5% were using vascular do
18  of lipid-lowering, blood pressure-lowering, antithrombotic drugs and diet and their place in the pre
19 tial for interference with the absorption of antithrombotic drugs and for an increased risk of bleedi
20 iography and assessed their association with antithrombotic drugs and mortality risk.
21   To estimate the association between use of antithrombotic drugs and subdural hematoma risk and dete
22   Increased knowledge of the pharmacology of antithrombotic drugs and the mechanisms underlying throm
23  properties of these most commonly used oral antithrombotic drugs, and explore the development of ant
24 , differences exist in the safety profile of antithrombotic drugs, and little is known about their in
25                                         Many antithrombotic drugs are eliminated mainly by the kidney
26                                              Antithrombotic drugs are used after coronary-artery sten
27                                              Antithrombotic drugs are widely used to prevent thrombot
28  A large unmet medical need exists for safer antithrombotic drugs because all currently approved anti
29 oprotection with aspirin use to selection of antithrombotic-drug composition, dosing and duration tai
30 mechanobiology, and holds great potential in antithrombotic drug development and assessing platelet a
31 ould be a candidate or lead compound for new antithrombotic drug development.
32 grade HAT was associated with higher odds of antithrombotic drug discontinuation during follow-up (od
33 onary syndrome (ACS) studies support similar antithrombotic drug efficacy, irrespective of sex, women
34         In Denmark from 2005 to 2018, use of antithrombotic drugs, especially VKAs, was associated wi
35 retically interesting therapeutic target for antithrombotic drugs for many years.
36 omplications and to the early institution of antithrombotic drugs, for both the prevention and therap
37                             Antiplatelet and antithrombotic drugs form the bedrock of management of p
38 ently new data on the efficacy and safety of antithrombotic drugs has become available.
39                                      Current antithrombotic drugs have an adverse effect on bleeding,
40                                      Several antithrombotic drugs have been proposed as potential the
41 usion of more severe strokes, greater use of antithrombotic drugs, higher doses, and the longer time
42 ggest that A1-A1 could be a prototype for an antithrombotic drug in APS.
43 al cardiopathy in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Str
44             However, the lack of data on new antithrombotic drugs including GII/GIIIA antagonists, fa
45                     On the other hand, these antithrombotic drugs increase bleeding in a population w
46                                           An antithrombotic drug is needed that safely reduces cardio
47  extent this is related to increasing use of antithrombotic drugs is unknown.
48                               Newly approved antithrombotic drugs maintain the need for updated revie
49  starting point for the development of novel antithrombotic drugs or chemical tools for studying the
50 pled P2Y purinoceptor 12, as an antiplatelet/antithrombotic drug, our data suggest that specifically
51 s to be associated with the increased use of antithrombotic drugs, particularly use of a VKA among ol
52 We compared the efficacy and safety of three antithrombotic-drug regimens - aspirin alone, aspirin an
53 imal use of combinations of antiplatelet and antithrombotic drugs requires improved methods for asses
54 nding the ischemic-bleeding risk tradeoff of antithrombotic drug reversal and removal strategies in t
55  Therapeutic interventions relying on prompt antithrombotic drug reversal or removal have been develo
56 eceptors are the targets of very widely used antithrombotic drugs such as clopidogrel, prasugrel, and
57 ctivation and thereby serves as an important antithrombotic drug target.
58 aggregation, and thus serves as an important antithrombotic drug target.
59 regulator of platelet activation and a novel antithrombotic drug target.
60 surface of platelets and that it could be an antithrombotic drug target.
61 is, providing a proof of concept for a novel antithrombotic drug target.
62 tivation and thrombus formation, and several antithrombotic drugs targeting P2Y12R--including the pro
63 eed for new molecular targets for developing antithrombotic drugs that minimally affect hemostasis.
64 ncreased bleeding and the development of new antithrombotic drugs, the use of alphaIIbbeta3 antagonis
65                     P2Y(12) is the target of antithrombotic drugs (ticlopidine, clopidogrel), whereas
66                   Upstream administration of antithrombotic drugs to patients with non-ST-segment ele
67 -1 (ICAM-1) targeting is suitable to deliver antithrombotic drugs to the pulmonary vascular lumen.
68 ), a direct oral anticoagulant, and combined antithrombotic drug treatment.
69 mortality and obligates clinicians to adjust antithrombotic drug type and dosing to avoid bleeding wh
70 ne trends in subdural hematoma incidence and antithrombotic drug use in the general population.
71                            The prevalence of antithrombotic drug use increased from 31.0 per 1000 ind
72                                  In Denmark, antithrombotic drug use was associated with higher risk
73              Subdural hematoma incidence and antithrombotic drug use was identified using population-
74                      Association of ICH with antithrombotic drug use, annual age- and sex-standardize
75        Association of subdural hematoma with antithrombotic drug use, subdural hematoma incidence rat
76 age (ICH) is the most severe complication of antithrombotic drug use.
77                           Treatment with any antithrombotic drug was comparable in the 2 groups (76.8
78                      Participants not taking antithrombotic drugs were excluded.
79                                              Antithrombotic drugs, which include antiplatelet and ant
80     In addition, the inappropriate dosing of antithrombotic drugs, which is not adapted to body weigh
81 tios (aORs) (95% CIs) for the association of antithrombotic drugs with ICH.
82 represents a potential target for developing antithrombotic drugs with minimal bleeding side effect.
83  discovery of new orthosteric and allosteric antithrombotic drugs with reduced adverse effects.
84 artly explained by differences in the use of antithrombotic drugs within the first 24 h of thrombolys